Dopamine Justice Alliance
  • Home
  • About
    • About DJA
    • Dopamine Agonists
    • Tribute to Dad
    • About the Founder
    • The Masterplan
  • Legal Action and Support
    • Victim & Family Support
    • Peer Support
    • Past Legal Successes
  • Research
    • Neuro Interconnections
    • Family Dynamics &Traits
    • SEN & Early Intervention
    • Culture & Environment
    • Dementia Diagnosis
  • News and Blog
  • Contact
  • Donate
  • More
    • Home
    • About
      • About DJA
      • Dopamine Agonists
      • Tribute to Dad
      • About the Founder
      • The Masterplan
    • Legal Action and Support
      • Victim & Family Support
      • Peer Support
      • Past Legal Successes
    • Research
      • Neuro Interconnections
      • Family Dynamics &Traits
      • SEN & Early Intervention
      • Culture & Environment
      • Dementia Diagnosis
    • News and Blog
    • Contact
    • Donate
Dopamine Justice Alliance
  • Home
  • About
    • About DJA
    • Dopamine Agonists
    • Tribute to Dad
    • About the Founder
    • The Masterplan
  • Legal Action and Support
    • Victim & Family Support
    • Peer Support
    • Past Legal Successes
  • Research
    • Neuro Interconnections
    • Family Dynamics &Traits
    • SEN & Early Intervention
    • Culture & Environment
    • Dementia Diagnosis
  • News and Blog
  • Contact
  • Donate

Dopamine Justice Alliance's Immediate Strategy

Dopamine Justice Alliance fights for victims devastated by dopamine agonist drugs like pramipexole and ropinirole, exposing hidden impulse control disorders that wrecked lives without adequate warnings.


Mission


Born from the tragedy of Alan John Williams—whose dopamine agonist medication unleashed sugar binges (up to 1kg+/day), substantial investment losses, between 50 and 100 infections, dozens of emergency hospitalisations (nearly 1 year inpatient 2015–2023), and a disputed 2017 vascular dementia label amid preserved capacity—the Alliance demands accountability from manufacturers (GSK, Boehringer Ingelheim) and NHS prescribers.

It provides emotional support, connects families, intends to fund legal action via CrowdJustice, and raises awareness of compulsions (binge eating, gambling, hypersexuality) amplified in vulnerable groups like those with kidney issues.


Key impacts and call to action


  • Victim stories: Share yours in strict confidence to build momentum, like Alan’s heroic endurance (scooter independence, sharp planning until end) despite suspected misdiagnosis and care failures (failed discharges, delayed CHC, delayed equipment, delayed rescue meds).
     
  • Campaign goals: Push for mandatory screening, Yellow Card enforcement, and class actions mirroring the Post Office scandal—contact MPs and the BBC (already engaged).
     
  • Get involved: Donate for publicity/legal aid, join support networks, or volunteer. Visit dopaminejusticealliance.org—together, turn silent suffering into systemic change.
     

The Numbers


Public data suggest that many tens of thousands of people in the UK are prescribed dopamine agonists at any one time, with English prescribing rates alone around 190 dopamine‑agonist prescriptions per 100,000 population between 2019 and 2024. Studies in Parkinson’s populations consistently find impulse control disorders in roughly 10–17% of those on dopamine agonists, which, applied cautiously to current UK usage, implies that many thousands of patients are likely to have been directly affected by compulsive side effects, and tens of thousands more family members and close contacts indirectly impacted by financial collapse, relationship breakdown, safeguarding issues and unresolved grief.pmc.ncbi.nlm.nih+1

​

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC12101742/
  2. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0324999

                  Dad's 48-hour dietary intake

  • Privacy Policy

Dopamine Justice Alliance

Copyright © 2026 Dopamine Justice Alliance - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept